Rocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation. It is used for both standard and rapid sequence induction (RSI). Rocuronium bromide competitively binds to the nicotinic receptor at the motor end plate, and antagonizes acetylcholine binding.

Product information

CAS Number: 119302-91-9

Molecular Weight: 609.68

Formula: C32H53BrN2O4

Synonym:

Zemuron

Rocuronium (Bromide)

Esmeron

UNII-I65MW4OFHZ

Esmerone

ORG 9426

ORG-9426

Related CAS Number:

143558-00-3 (Rocuronium cation)

Chemical Name: [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17R)-3-hydroxy-10, 13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;bromide

Smiles: [Br-].CC12CCC3C(CCC4CC(O)C(CC43C)N3CCOCC3)C1CC(C2OC(C)=O)[N+]1(CC=C)CCCC1

InChiKey: OYTJKRAYGYRUJK-UHFFFAOYSA-M

InChi: InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 122 mg/mL(200.1 mM). Water: 122 mg/mL(200.1 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.

In Vivo:

Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in isoflurane anesthetized horses. Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats.

References:

1. Auer U, et al. Vet Ophthalmol,?011, 14(4), 244-247.
2. Anzenbacherova E, et al. J Pharmacol Sci,?015, 127(2), 190-195.
3. Zan U, et al. Cytotechnology,?011, 63(3), 239-245.

Products are for research use only. Not for human use.